All In Biotech

Drug Trial Radar · NCT05329623

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants.

Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

May 3, 2022

Primary completion

Apr 7, 2024

Study completion Apr 7, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.

Conditions

  • Small Cell Lung Carcinoma

Interventions

  • JDQ443Drug

    All the participants will receive a single oral dose of JDQ443.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  2. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  3. Maximum Observed Plasma Concentration (Cmax) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  4. Time to Reach the Maximum Concentration of JDQ443 After Drug Administration (Tmax) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  5. Time of observation prior to the first observation with a measurable concentration (Tlag) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  6. Terminal Elimination Half-life (T1/2) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  7. Apparent Total Body Clearance From Plasma (CL/F) of JDQ443 following Drug AdministrationTime frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  8. Apparent Volume of Distribution of JDQ443 during Terminal Phase (Vz/F)Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  9. Area Under the Plasma Concentration-time Curve from Time Zero to time "t" (AUC0-t) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose
  10. Latest pharmacokinetic sampling time with a measurable concentration (Tlast) of JDQ443Time frame: Day 1 (Pre-dose), 0.5, 1, 1.5, 2, 3 , 4 , 6 , 8 , 12 , 24 , 36 , 48 and 72 hours post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orlando Clinical Research Center

    Orlando, Florida

  • Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.